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Background: Despite advances in radiation therapy, chemotherapy, and newly developed molecular targeting
therapies, long-term survival after resection for patients with NSCLC remains less than 50%. We investigated factors
predicting postoperative locoregional recurrences and distant metastases in patients with clinical stage I
non-small-cell lung cancer (NSCLC) after surgical resection.
Methods: All patients with clinical stage I NSCLC, who underwent surgical resection between January 2002 and
June 2006, were reviewed retrospectively. Multiple logistic regression analyses were used to identify independent
risk factors for patients with locoregional recurrences and distant metastases.
Results: A total of 261 patients were eligible. Overall survival was significant related to locoregional recurrences
(P = 0.03) and distant metastases (P <0.001). There were significant differences of locoregional recurrence in tumor
differentiation (P = 0.032) and advanced pathological stage (P = 0.002). In the group of distant metastases, there
were significant differences in tumor differentiation (P = 0.035), lymphovascular space invasion (P = 0.031). Among
the relationship between pattern of distant metastasis and clinicopathologic variables in patients with clinical stage
I NSCLC, SUVmax (P = 0.02) and tumor size (P = 0.001) had significant differences. According to multiple logistic
regression analysis, tumor differentiation is the only risk factor of postoperative outcome for locoregional recurrence
and serum CEA (>3.5 ng/mL) is the predictor of distant metastasis.
Conclusions: Tumor differentiation and serum CEA were predictors of postoperative relapse for clinical stage I
NSCLC after surgical resection. Risk factors of postoperative recurrence in patients with clinical stage I NSCLC may
enable us to optimize the patient selection for postoperative adjuvant therapies or neoadjuvant treatment
before surgery.
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Non-small-cell lung cancer (NSCLC) remains the leading
cause of cancer-related death and has a dismal prognosis.
Despite advances in radiation therapy, chemotherapy, and
newly developed molecular targeting therapies, long-term
survival after resection for patients with NSCLC remains
less than 50%. Most mortality following surgical resection
is associated with tumor recurrence. Studies have investi-
gated the clinical, pathological, and genetic factors that* Correspondence: addgujfjui@gmail.com
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reproduction in any medium, provided the orare associated with decreased survival after resection for
NSCLC [1,2]. Nodal metastasis or occult micrometas-
tasis might be a key-link of postoperative recurrence
in patients with stage I NSCLC. Our study investi-
gated factors predicting postoperatively locoregional
recurrence or distant metastasis in patients with clinical
stage I NSCLC after surgical resection. These clinicopath-
ologic variables could be available before surgery and
enable us to optimize the patient selection for postopera-
tively adjuvant therapies or preoperatively neoadjuvant
treatment in order to reduce recurrences and improving
survival rate.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The relationship of overall survival rate between with
and without locoregional recurrences in clinical stage I NSCLC.
Cum, cumulative; OS, overall survival.
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A retrospective examination was performed of a prospect-
ively maintained database of patients who underwent sur-
gical resection for clinical stage I NSCLC from January
2002 to June 2006 at Tri-Service General Hospital, Taiwan.
The preoperative staging work-up included chest and
upper abdomen computed tomography (CT) scans, bron-
choscopic examination, nuclear medicine survey (bone
and brain), and whole body positron emission tomography
(PET) scan. Mediastinoscopy was not a routine preopera-
tive staging procedure, and was performed only when en-
larged mediastinal lymph nodes (diameter >1.0 cm) shown
by the CT scan to prove nodal status of staging. All pa-
tients underwent surgical intervention for cure. Patients
were excluded if they had carcinoid histological type, sec-
ond lung primary lesions, or died within 30 days of oper-
ation. The selected cases were staged according to
the seventh edition of the American Joint Committee on
Cancer adopted in 2009 [3]. After evaluation of the resect-
ability and operability of the tumors, a total of 261 patients
with clinical stage I NSCLC were enrolled and underwent
surgical resection with dissection of the mediastinal lymph
nodes. Serum carcinoembryonic antigen (CEA) level was
measured as a part of the routine preoperative evaluation
and postoperative follow-up. Serum CEA level was calcu-
lated by means of the two-site immunoenzymometric
assay (CEA test; CIS Bio International, France; reference
range <5.0 ng/mL) following the manufacturer’s instruc-
tions. The upper limit of normal in our hospital defined as
3.5 ng/mL based on the 95% specificity level for benign
lung disease.
Postoperatively, patients were initially seen at 2 to 3
weeks after resection by the thoracic surgeon and then
again every 3 to 6 months; they underwent contrast-
enhanced chest CT at these appointments during the
follow-up period. The serum CEA level was routinely
measured after surgery every 3 months. Subsequent to
these visits, either a roentgenogram or CT scan of the
chest was reviewed annually. PET with CT or magnetic
resonance imaging was used as clinically warranted. All
visits were completed in concert with the referring on-
cologist. Recurrence was documented either radio-
graphically or histologically in all cases.
Second primary lung cancer was differentiated from
recurrent NSCLC according to the criteria proposed by
Martini [4]. Clinicopathologic variables were investigated
for their influence on time to locoregional recurrences
and distant metastasis. For evaluation of surgical prog-
nosis, patients with locoregional recurrences or distant
metastases were independently analyzed and discussed.
Locoregional recurrence was defined as tumor recur-
rence in contiguous anatomical sites, including the ipsi-
lateral hemithorax and ipsilateral mediastinal or hilar
lymph nodes, or both after surgical resection. Distantmetastasis was defined as tumor recurrence in the
contralateral lung or outside the hemithorax and medi-
astinum after surgical resection.
Statistical analysis
Descriptive data are expressed as the mean ± standard de-
viation. Student’s t test was used to investigate continuous
variables and the χ2 test was used to compare categorical
variables between these groups. Survival from the date of
surgery was calculated using Kaplan-Meier survival ana-
lysis. Multiple logistic regression analyses were used to
identify independent risk factors for patients with locore-
gional recurrences and distant metastases. SPSS 14.0 soft-
ware (SPSS, Inc., Chicago, IL, USA) was used for all
analyses and statistical significance was defined as P <0.05.
Results
Two hundred sixty-one patients with clinical stage I
NSCLC after complete resection and dissection of medias-
tinal lymph nodes were reviewed. In our study, 17 patients
(6.5%) of the total of 261 patients had locoregional recur-
rences and 20 (7.66%) of the same population had distant
metastases. The most common site of locoregional recur-
rence is ipsilateral lung (10/17, 58.82%) and that of distant
metastasis are brain (9/20, 45%) and bone (8/20, 40%).
Three of 17 patients with locoregional recurrence had
pleural disseminations and the other four patients had me-
diastinal lymph node recurrences. Two of 20 patients with
distant metastasis had liver metastases and only one pa-
tient had adrenal gland metastasis.
Figure 1 reveals the relationship between cumulative sur-
vival rate and overall survival in patients with locoregional
recurrence. The median survival showed 112.53 months in
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with recurrence (P = 0.03). Figure 2 showed the relationship
between cumulative survival rate and overall survival in pa-
tients with distant metastasis. The median survival showed
112.53 months in patients without metastasis versus
40.26 months in patients with recurrences (P <0.001).
Therefore, surgical outcome of these patients is associated
with postoperative recurrences.
The demographic characteristics in patients with clinical
stage I NSCLC are shown in Table 1. Recurrences are sub-
divided into locoregional recurrences and distant metasta-
ses. There were no significant differences in sex (P = 0.806;
P = 0.989), tumor histopathology (P = 0.14, P =0.322),
tumor location (P = 0.324; P =0.494), and different surgical
procedures (P = 0.609; P =0.620). Comparisons between
two groups showed statistical significance only in tumor
differentiation (P = 0.032; P = 0.035). Seventy-five patients
(75/244, 30.74%) in the group without locoregional recur-
rence had postoperative upstaging versus seven patients
(7/17, 41.18%) with recurrence (P = 0.002). There were 20
distant metastases, representing 7.66% of the population
studied. These data without significant differences in
locoregional recurrence and with significant difference in
distant metastasis were administration of adjuvant chemo-
therapy (P = 0.44; P <0.001), lymphovascular space inva-
sion (LVSI) (P = 0.214; P =0.031).
Table 2 illustrates the association of clinicopathologic var-
iables to predict the locoregional recurrence or distant me-
tastasis. These factors included age, preoperative SUVmax
of tumor, tumor size, and serum CEA level. Despite of no
significant difference in SUVmax of tumor and CEA level,
patients with locoregional recurrence still have higher value
than patients without recurrence. Those in the distant
metastasis group had a higher SUVmax (4.44 ± 3.96 vs.Figure 2 The relationship of overall survival rate between with
and without distant metastasis in clinical stage I NSCLC. Cum,
cumulative; OS, overall survival.6.69 ± 4.39, P = 0.020) and larger tumor size (2.67 ± 1.49 cm
vs. 3.83 ± 1.41 cm, P = 0.001). The preoperative CEA levels
(5.01 ± 12.65 ng/mL vs. 10.31 ± 23.34 ng/mL, P = 0.346) was
not significantly associated with distant metastasis, which
was obviously more than that without distant metastasis.
In the multiple logistic regression analysis (Table 3), poor
tumor differentiation (odds ratio (OR): 4.902, P = 0.007)
was the only independent risk factor associated with
postoperatively locoregional recurrence. Preoperative
SUVmax ≥3.3 (OR: 1.193, P = 0.766), CEA ≥3.5 ng/mL
(OR: 2.545, P = 0.110), tumor size >2 cm (OR: 1.243,
P = 0.721), and LVSI (OR: 2.103, P = 0.336) did not predict
postoperatively locoregional recurrence. The only independ-
ent predictor of postoperatively distant metastasis was
preoperative serum CEA ≥3.5 ng/mL (OR: 3.505, P = 0.029).
In the Figure 3, the CEA level can also predict disease-free
survival after operation (P <0.001).
Discussion
Lung cancer has the highest incidence and mortality rates
of any major cancer worldwide. The 5-year survival rate
has been reported as 73% for patients with pathology stage
IA and 58% for pathological stage IB [5]. After apparent
complete resection in patients with stage I disease, the re-
currence rates range from 25% to 50% [6]. In our study,
we utilize the same population to probe into surgical out-
come on the occurrence of locoregional recurrence or
distant metastasis. Figures 1 and 2 showed significant dif-
ferences between overall survival and postoperative recur-
rences. The survival rate is strongly associated with
locoregional recurrence or distant metastasis. The mech-
anism of postoperative recurrence was not well established
to date. Godfrey et al. [7] stated that one possible reason
for this may be that those patients with a poor outcome
actually have more extensive disease, with occult locore-
gional and/or distant metastasis than originally identified
by routine pathologic staging techniques. One of the most
convinced etiology of postoperative recurrence was occult
tumor cell spreading to lymph nodes or bone marrow in
patients with NSCLC [7]. Chakrabarti et al. [8] thought
the detection of bone marrow micrometastasis changes
the staging and management of lung cancer, especially
in NSCLC, where treatment with curative intent is
planned, which can be suitably done by morphological
study of bone marrow aspirate and biopsy. However, the
cost effect of bone marrow aspiration is high and the
invasiveness of the procedure may produce more com-
plications. Therefore, we searched clinicopathologic fac-
tors, which were cost-effective and available before
surgery, to predict postoperative recurrences in patients
with clinical stage I NSCLC. Then, we could optimize
the patient selection for neoadjuvant systemic therapy
or postoperatively adjuvant treatment to reduce recur-
rent rate and improve survival rate.
Table 1 Characteristics of patients with or without loco-regional recurrence and distant metastasis after resection for
clinical stage I NSCLC
Locoregional recurrence Distant metastasis
No (n = 244) (100%) Yes (n = 17) (100%) p-valuea No (n = 241) (100%) Yes (n = 20) (100%) p-valuea
Sex:
Male 110 (45.08) 7 (41.18) 0.806 108 (44.81) 9 (45) 0.989
Female 134 (54.92) 10 (58.82) 133 (55.19) 11 (55)
Histopathology:
Adenocarcinoma 209 (85.66) 17 (100) 0.140 210 (87.14) 16 (80) 0.322
Other 35 (14.34) 0 (0) 31 (12.86) 4 (20)
Differentiation:
Well 98 (40.16) 4 (23.53) 99 (41.08) 3 (15)
Moderate 97 (39.75) 5 (29.41) 0.032 93 (38.59) 9 (45) 0.035
Poor 49 (20.08) 8 (47.06) 49 (20.33) 8 (40)
Location:
Central 125 (51.23) 11 (64.71) 0.324 124 (51.45) 12 (60) 0.494
Peripheral 119 (48.77) 6 (35.29) 117 (48.55) 8 (40)
Adjuvant chemotherapy:
Yes 89 (36.48) 8 (47.06) 0.440 80 (33.2) 3 (15) < 0.001
No 155 (63.52) 9 (52.94) 161 (66.8) 17 (85)
LVSI:
Absent 222 (90.98) 14 (82.35) 0.214 221 (91.7) 15 (75) 0.031
Present 22 (9.02) 3 (17.65) 20 (8.3) 5 (25)
Operation:
Lobectomy 228 (93.44) 17 (100) 0.609 225 (93.36) 20 (100) 0.620
Wedge 16 (6.56) 0 (0) 16 (6.64) 0 (0)
p-stage:
I 169 (69.26) 10 (58.82) 0.002 168 (69.71) 11 (55) 0.232
II 44 (18.03) 3 (17.65) 40 (16.60) 7 (35)
III 31 (12.71) 3 (17.65) 32 (13.28) 2 (10)
IV 0 (0) 1 (5.88) 1 (0.41) 0 (0)
aSignificance was assessed using χ2 tests. Key: SCC, squamous cell carcinoma; LVSI, lymphovascular space invasion; p-stage, pathology stage.
Statistically significant p values are depicted in underline.
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tic factors were poor tumor differentiation and advanced
pathology stage (Table 1). Furthermore, no parameters
were identified as independent risk factors (Table 2). Be-
sides, the poor prognostic variables in patients with clin-
ical stage I NSCLC who developed distant metastasis
after surgical resection included poor tumor differenti-
ation, absence of adjuvant chemotherapy, and advanced
pathologic staging (Table 1). In the adjusted association
of clinicopathologic variables with distant metastasis, the
independent risk factors were SUVmax of tumor and
tumor size (Table 2). In the multiple logistic regression
analysis (Table 3), poor tumor differentiation (OR: 4.902,
P = 0.007) was the only independent risk factor associ-
ated with postoperatively locoregional recurrence. The
only independent predictor of postoperatively distantmetastasis was preoperative serum CEA ≥3.5 ng/mL
(OR: 3.505, P = 0.029). We would like to discuss these
variables in the following subject matter.
Preoperative clinical staging is a key factor influencing
the decision on the initial therapy for patients with lung
cancer. In this regard, PET-CT with fluorodeoxyglucose
(18F) uptake (FDG) plays an established role in the treat-
ment of patients with NSCLC. FDG uptake, which re-
flects the tumor’s glucose metabolic rate, varies widely
and depends on the histopathology type and aggressive-
ness of the tumor [9,10]. Consideration of this parameter
enhances the accuracy of clinical staging, improving pa-
tient selection for surgical treatment. Several studies
have reported that the preoperative SUVmax has prog-
nostic value in patients with early stages of NSCLC
[11,12]. Cerfolio et al. [13] reported a large series of 315
Table 2 Relationship between pattern of locoregional recurrence and distant metastasis with clinicopathologic
variables in patients of clinical stage-I NSCLC
Variables Locoregional recurrence Distant metastasis
No (n = 244) Yes (n = 17) p-valuea No (n = 241) Yes (n = 20) p-valuea
Age (y) 61.51 ± 12.32 59.94 ± 10.14 0.609 61.11 ± 12.33 65.00 ± 9.82 0.170
SUVmax of tumor 4.55 ± 4.05 5.79 ± 3.91 0.251 4.44 ± 3.96 6.69 ± 4.39 0.020
Tumor size (cm) 2.76 ± 1.54 2.76 ± 1.07 0.991 2.67 ± 1.49 3.83 ± 1.41 0.001
CEA (ng/mL) 4.59 ± 9.29 14.58 ± 33.44 0.267 5.01 ± 12.65 10.31 ± 23.34 0.346
aSignificance was assessed using Student’s t tests; SUVmax: maximum standard uptake value; CEA: carcinoembryonic antigen.
Statistically significant p values are depicted in underline.
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SUVmax correlated with stage, recurrence, and survival.
SUVmax ≥10 was the best independent predictor of
disease-free survival and overall survival. Koo et al. [14]
investigated factors associated with recurrence in 310
patients with stage I or II disease. There were 106 recur-
rences in the study population and a SUVmax ≥4.5 was
found to be an independent predictor of recurrence after
resection, with an OR of 5.45. The study did not stratify
patients based on the location of recurrence to deter-
mine whether SUVmax was more predictive for locore-
gional than for distant recurrences. In another study,
subgroup analysis found that a SUVmax >5 was associ-
ated with distant recurrences, whereas the predictive na-
ture of SUVmax >5 did not reach statistical significance
among patients with locoregional recurrences [15]. Al-
though the metabolic activity of tumors has been shown
to contribute significant information in terms of progno-
sis [16,17], the cutoff values for SUV measurements vary
widely, making their clinical application difficult. In our
study, the cutoff point of SUVmax of 3.3 was used ac-
cording to our previous study [18]. However, the SUV-
max of our results did not show statistical significance
in prediction of locoregional recurrences and distant
metastases.
There was concordance between the pathological stage
and the preoperative clinical stage in 68.58% of patients
in our both groups. Therefore, 82 patients (31.42%) had
advanced disease upon the proof of pathologic stage.Table 3 Multiple logistic regression analysis for locoregional
clinical stage-I NSCLC
Factor Locoregional recurrence
OR (95% CI) p
SUVmax 3 3.3 1.193 (0.373–3.818)
CEA 3 3.5 ng/mL 2.545 (0.810–8.001)
Tumor size > 2 cm 1.243 (0.377–4.098)
Differentiation 4.902 (1.541–15.625)
LVSI 2.103 (0.462–9.573)
Key: OR, odds ratio; CI, confidence interval. Differentiation: non-poor/poor.
Statistically significant p values are depicted in bold print.This was higher than the rates of upstaging tumors of
14.3% to 17% reported in the literature [19,20]. Varlotto
et al. investigated factors associated with recurrence in
373 patients with stages I through IIIA NSCLC who
underwent complete resection. An advanced pathologic
stage was associated with an increased risk of distant re-
currence [21]. Although the study established the import-
ance of the pathological stage for the risk of recurrence,
they used the sixth edition not the most recent seventh
edition of the TNM staging system. Pepek et al. [22] com-
pared the ability of the seventh edition TNM staging sys-
tems to detect locoregional recurrence in comparison to
the sixth edition. Converting from the system used in the
sixth edition to that in the seventh edition resulted in a
21% migration in stage classification (13% upstaged and
8% downstaged). This might explain the high rate of post-
operative upstaging in our study, because we used the sev-
enth edition of the TNM staging system for all patients. In
our study, the rate of locoregional recurrence was 6.51%
(3.83% for pathological stage I and 2.68% for non-stage I).
A pathologic stage greater than I was independently asso-
ciated with a higher risk of recurrence. Tumor differenti-
ation, absence of adjuvant chemotherapy, and LVSI
significantly associated with distant metastasis for clinical
stage I NSCLC. But, the locoregional recurrences were
only significantly related with tumor differentiation. The
patients, who received adjuvant chemotherapy, got signifi-
cantly lower rates of distant metastasis and better survival
rates. Therefore, adjuvant chemotherapy may need to berecurrences and distant metastases in patients with
Distant metastasis
-value OR (95% CI) p-value
0.766 1.430 (0.470–4.735) 0.608
0.110 3.505 (1.138–10.795) 0.029
0.721 3.349 (0.668–16.782) 0.142
0.007 1.615 (0.186–2.062) 0.434
0.336 1.430 (0.365–5.601) 0.608
Figure 3 The relationship of DFS and CEA level in clinical stage
I NSCLC. The CEA level can predict DFS after operation (the blue
line: CEA <3.5 ng/mL; the green line: CEA >3.5 ng/mL; P <0.001).
CEA, carcinoembryonic antigen; cum, cumulative; DFS,
disease-free survival.
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A prospective randomized study will be needed to clarify
this issue.
Sublobar resection has been found to be an independent
predictor of locoregional recurrence [15]. Tumor size in
that report was not associated with an increased risk of re-
currence in the sublobar resection group (2.3 cm in the
group with recurrence, 2.2 cm in the group without recur-
rence; P <0.3). In contrast, Bando et al. [23] reported
higher recurrent rate is associated with sublobar resection
in patients with tumors >2 cm. In their study, patients
with tumors <2 cm had locoregional recurrence rates of
1.9% compared with 33% in patients with tumors >2 cm.
The different conclusions in these studies might be associ-
ated with the larger sample size in the former study and
the fact that only 50% of the patients underwent wedge re-
section. In contrast, all patients underwent segmentectomy
in the latter study. In our present study, only 16 patients
had wedge resection and others underwent lobectomy. For
patients with tumor diameters <2 cm, the postoperative re-
currence rate was 6.1% versus 19.4% for patients with tu-
mors >2 cm. After adjustment for the other factors, tumor
size with a cutoff of 2 cm was not found to be an independ-
ent predictive factor in the multiple logistic regression ana-
lysis for patients of NSCLC.
Furthermore, histopathology markers were found to be
prognostic predictors in patients with NSCLC [24]. CEA
is a well-known tumor marker for substantial malignant
tumors, including NSCLC. Evaluating serum CEA level
is useful for monitoring response to chemotherapy and
predicting relapse of advanced NSCLC [25]. Sawabata
et al. [26] assessed 297 consecutive patients with clinicalstage I NSCLC for evaluation of CEA level and the
upper limit of normal defined as 7.0 ng/mL. They saw
the CEA level as a useful predictor of survival for pa-
tients with clinical stage I NSCLC, and a persistently
high CEA level after surgery as an especially strong indi-
cator of a very poor prognosis. In another study, Buc-
cheri et al. [27] reported the frequency of abnormal
serum concentrations of CEA is low (17%), but it is im-
portant to identify such a small group of high-risk pa-
tients as many of them (55% and 70% of those with a
CEA value in excess of 5 and 10 ng/mL, respectively;
normal reference values <5 ng/mL) will develop an early
postoperative recurrence. Despite of significant differ-
ence in serum CEA level in both groups of our study,
CEA levels (≥3.5 ng/mL) was only an independent pre-
dictive factor for postoperative distant metastasis after
adjustment of the other factors. The CEA level can also
predict disease-free survival after operation. Then after
an apparently successful operation, patients with clinical
stage I NSCLC should be carefully followed up by inten-
sified imaging study or close intervals. These patients
could represent a suitable target for neoadjuvant clinical
trials of selected high-risk groups. Apparently, they also
received benefits from adjuvant chemotherapy with bet-
ter survival rates in our study.
From literature review, Subotic et al. [28] stated that the
intensified follow up did not increase either the proportion
of patients detected with asymptomatic relapse or the
number of patients with specific oncological treatment of
relapse. However, the above follow-up method was regular
monthly telephone contact with patients and/or their fam-
ilies in order to get reliable information about the patient’s
general condition and eventual new complaints that were
not present on discharge. We did not think the above
follow-up method was a good way of early detection ac-
cording to patient’s symptoms, because recurrent malig-
nancy would be asymptomatic. The follow-up methods
and intervals were more important for early detection of
the recurrence. In our study, regular follow-up with im-
aging study and routinely measuring serum CEA level
would be a better method for detection of small or occult
recurrent lesions.
As a retrospective, single-center study, patient-selection
bias and time-trend bias were inevitable. It was difficult to
obtain performance status from the charts. Although per-
formance status is clearly an important factor in stage IV
NSCLC, its importance in stage I disease has not yet been
established. Lack of data about performance status might
have little significance in the analysis of death and recur-
rence in our study. The 261 patients were operated on by
different surgeons. As we know, different surgeons have
different levels of dexterity, leading to different rates of re-
currence. Furthermore, the fact that the predictors dem-
onstrated in our study were not all consistent with other
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More data are needed with a larger sample of patients and
longer follow-up. Further studies of clinical information
combined with histopathological markers might provide
valuable indicators for recurrences. Prospective multi-
institutional studies are mandatory to validate the predic-
tors of recurrence in clinical stage I NSCLC.
Conclusion
Tumor differentiation and serum CEA were predicators of
postoperative relapse for clinical stage I NSCLC after sur-
gical resection. Risk factors of postoperative recurrence in
patients with clinical stage I NSCLC may enable us to
optimize the patient selection for postoperative adjuvant
therapies or neoadjuvant treatment before surgery.
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